Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3161-3167

  Charara, Mona ^a   Edmonston, Tina Bocker ^a   Burkholder, Susan ^b   Walters, Rhonda ^a   Anne, Pramila ^a   Mitchell, Edith ^a   Fry, Robert ^c   Boman, Bruce ^a   Rose, Deborah ^c   Fishel, Richard ^b   Curran, Walter ^a   Palazzo, Juan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell cycle proteins; Irinotecan; Microsatellite instability; Neoadjuvant therapy; Rectal cancer

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); FLUOROURACIL; IRINOTECAN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; FLUOROURACIL; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 6344260289     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Garfinkel L and Mushinski M: U.S. cancer incidence, mortality and survival: 1973-1996. Stat Bull Metrop Insur Co 80: 23-32, 1999.
2. Hemminski A, Mecklin JP, Järvinen H, Aaltonen LA and Joensuu H: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119: 921-928, 2000.
3. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu S, Redston M et al: Tumor microsatellite-instability status as a predictor of benefit from Fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
4. Bocker T, Rueschoff J and Fishel R: Molecular diagnostics of cancer predisposition: Hereditary non-polyposis colorectal carcinoma and mismatch repair defects. BBA (Reviews on cancer) 1423: O 1-O 10, 1999.
5. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R and Rüschoff J: Diagnostic microsatellite instability: Definition and correlation with mismatch protein expression. Cancer Res 57: 4749-4756, 1997.
6. De La Chapelle: Microsatellite instability phenotype of tumors: Genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 20: 897-899, 2000.
7. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L and Srivastava S: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Nat Cancer Inst 89: 1758-1762, 1997.
8. WAF1/C1PI and bcl-2 in radioresistant colorectal carcinoma. Hum Path 28: 1189-1195, 1997.
9. Sgambato A, Ratto C, Faraglia B, Merico M, Ardito R, Schinzari G, Romano G and Cittadini ARM: Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27 kip1 in human colon cancer. Molecular Carcinog 16: 172-179, 1999.
10. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H and Weinstein IB: Localization and expression of p27 in multistage colorectal carcinogenesis. Cancer Res 58: 114-122, 1997.
11. Bocker Edmonston T, Cuesta K, Burkholder S, Barusevicius A, Rose D, Kovatich A, Boman B, Fry R, Fishel R and Palazzo JP: Colorectal carcinoma with high microsatellite instability: Defining a distinct immunologic and molecular entity with respect to prognostic markers. Human Path 31: 1506-1514, 2000.
12. Buglioni S, D'Agnano I, Cosimelli M, Vaselli S, D'Angelo C, Tedesco M, Zupi G and Mottolese M: Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 84: 545-552, 1999.
13. Sinicrope FA, Hart J, Michelassi F and Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1: 1103-1110, 1995.
14. Tollenaar RAEM, Van Krieken JHJM, Van Slooten HJ, Bruinvels DJ, Nelemans KMJ, Van den Broek LJ, Hermans J and Van Dierendonck JH: Immunohistochemical detection of p53 and bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 77: 1842-1847, 1998.
15. Saltz L: Irinotecan in the first-line treatment of colorectal cancer. Oncology 12: S54-S58, (suppl 6), 1998.
16. Goldberg R and Erlichman C: Irinotecan plus 5-FU and Leucovorin in advanced colorectal cancer: North American trials. Oncology 12: S59-S63, (suppl 6), 1998.
17. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S and Rustum YM: Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19: 1501-1518, 2001.
18. Magrini R, Bhonde M, Hanski ML and Notter MS: Cellular effects of CPT-11 on colon carcinoma cells: Dependence on p53 and hMLH1 status. Int J Cancer 101: 23-31, 2002.
19. Szumiel I, Buracewska I, Gradzka I and Gasinska A: Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive. Int J Radiat Biol 67: 441-448, 1995.
20. Boland R, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriquez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.
21. Hsiang Y, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized Topoisomerase I- DNA cleavable complexes as a mechanism of cell killing by Camptothecin. Cancer Res 49: 5077-5082, 1989.
22. Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M and Praz F: Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63: 5738-5744, 2003.
23. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD and Howell SB: p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61: 1508-1516, 2001.
24. Brentnall T, Crispen D, Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS, Rubin CE, Haggitt RC and Boland CR: Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 56: 1237-1240, 1996.
25. Fleisher S, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM and Kong D: Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 60: 4864-4868, 2000.